Sunitinib is an orally administered inhibitor of tyrosine kinases and has become the standard of care for many patients with metastatic renal cell carcinoma. Its use has been associated with renal toxicity in some patients. We report a patient with a metastatic clear-cell renal carcinoma who showed arterial hypertension, nephrotic syndrome and azotaemia 10 months after treatment with sunitinib....

INTRODUCTION Renal cell carcinoma is a common adult malignancy that can present incidentally or with a multitude of clinical symptoms and signs. Metastatic spread is frequent, occurring via haematogenous and lymphatic routes, although it does not typically present with lymphangitis carcinomatosa. CASE PRESENTATION We describe a patient who presented with cough and increasing dyspnoea. Initial...

background and objective: evaluation of tumor proliferative activity may provide a predicting parameter to estimate biologic aggression and a subsequent prognosis that has been evaluated in many malignancies. we have selected renal cell carcinoma (rcc) in this study. to determine tumor proliferative activity, ki67 antibody was applied and results were compared with apoptosis, applying p53 antib...

the coexistence of two malignancies is rarely seen. a little association between hematologic malignancies especially multiple myeloma and renal cell carcinoma has been reported in the recent past. several case series revealed a bidirectional association between these two malignancies which may be due to the common risk factors, similar cytokine growth requirements and clinical presentation. her...

Renal cell carcinoma can metastasize to virtually any organ, yet synchronous metastasis to the bladder is extremely rare. A 77-year-old woman presented with gross hematuria. Abdominal and chest computed tomography showed a bilateral renal masses, bladder dome mass, and multiple lung metastasis. Transurethral resection of the bladder tumor and sonography guided renal biopsy were performed. Both ...

INTRODUCTION Papillary renal cell carcinoma (PRCC), which represents around 20% of renal cell carcinomas, is a heterogeneous disease that includes different tumor types with several clinical and molecular phenotypes. Nivolumab, a fully human IgG4 programed cell death protein 1 immune checkpoint inhibitor antibody, has shown not only an overall survival advantage when compared to everolimus but ...

UNLABELLED BACKGROUND Targeted therapies in renal cell carcinoma can have different effects on primary and metastatic tumors. To pave the way for predictive biomarker development, we assessed differences in expression of targets of currently approved drugs in matched primary and metastatic specimens from 34 patients. METHODS Four cores from each site were embedded in tissue microarray bloc...

OBJECTIVE To address the role of serum gamma-glutamyl transferase (GGT) as a marker of metastases in patients with renal cell carcinoma. METHODS Serum alkaline phosphatase and GGT were determined in 156 patients with localized renal cell carcinoma and 60 patients with metastases as proven by echosonography, computerized tomography and bone scan. The control group consisted of 50 healthy subje...

renal masses can be categorized as benign and malignant lesions. among the renal malignancies, renal cell carcinoma is the most common malignancy. however, other rare malignant lesions should be considered in differential diagnosis. primary renal lymphoma is quite rare and might be mistaken for renal cell carcinoma. due to lack of lymphatic tissue in the kidney, pathogenesis of renal lymphoma i...

objective(s): renal cell carcinoma (rcc) is insensitive to conventional chemotherapy. ginkgetin effectively treats several carcinoma cells. however, little is known about effects of ginkgetin on rcc. in the present study, using 786-o cells, we evaluate whether ginkgetin exerts anticancer effects against rcc. materials and methods: 786-o cells suspended in the medium containing ginkgetin were cu...